Grace Therapeutics, Inc.
Grace Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for neurological disorders. Founded in 2015, the company has made significant strides in advancing its proprietary drug delivery systems, particularly in the treatment of conditions such as epilepsy and other central nervous system disorders. With a commitment to enhancing patient outcomes, Grace Therapeutics offers unique formulations that improve the bioavailability and efficacy of existing medications. Their cutting-edge approach has positioned them as a leader in the biopharmaceutical industry, garnering recognition for their contributions to drug development. As they continue to expand their operational reach, Grace Therapeutics remains dedicated to transforming the landscape of neurological treatment through science and innovation.
DitchCarbon Score
How does Grace Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Grace Therapeutics, Inc.'s score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Grace Therapeutics, Inc.'s reported carbon emissions
Grace Therapeutics, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data or specific reduction targets. Without reported emissions figures, it is unclear how the company is addressing its carbon footprint or what commitments it has made towards climate action. In the absence of concrete data, it is essential to note that many companies in the industry are increasingly focusing on sustainability and setting ambitious targets to reduce their greenhouse gas emissions. Grace Therapeutics may be part of this broader trend, but specific details regarding their climate commitments or initiatives remain unspecified.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Grace Therapeutics, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
